ANGPTL4 and hypertriglyceridemia: At the same time, the novel understanding of immune-metabolic crosstalk in HSCs could contribute to depict collateral effects of developing lipid-lowering therapies, as the recent application of Angptl4 inhibitors for the treatment of hypertriglyceridemia that, despite promising, could bear activation of LPL in macrophages thus promoting their inflammatory activation [84].